ArticleScientific reports2025
In silico design of novel multi-epitope peptide vaccine against Neospora caninum induced cattle abortion targeting extracellular GRA2 and Nc-p43 protein.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Computationally guided multi-epitope vaccine design targeting oncoprotein BZLF1, EBNA1, LMP1, and LMP2 for of EBV associated gastric cancer.Journal of the Egyptian National Cancer Institute · 2026Article
- Designing a chimeric multi-epitope vaccine against Candida auris using reverse vaccinology approach targeting the agglutinin-like protein N-terminal domain.Scientific reports · 2026Article
- A conserved capsid-based multi-epitope vaccine targeting dengue virus serotypes (DENV1-4): an integrated computational and in vivo study.BMC immunology · 2026Article
- Molecular characterization and immunoinformatics-based design of a multi-epitope vaccine against Staphylococcus nepalensis.Antonie van Leeuwenhoek · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neospora caninum (NC) is a protozoan infection causing neosporosis, a disease that leads to substantial economic loss in livestock, especially in cattle, sheep, and goats. Unfortunately, there is presently no viable vaccination or authorized therapy available. Our research applied a bioinformatics approach to design a multi-epitope peptide (MEP) vaccine aimed at the pathogenic proteins GRA2 and Nc-p43 of NC, which are critical in parasite-mediated antigenicity and host interactions. Consequently, our research employs an in-silico methodology, including protein sequence retrieval, epitope prediction, vaccine design, structural analysis, molecular docking, molecular dynamics simulations, immunological simulation, and codon optimization using in silico cloning. We conducted analyses of antigenicity, allergenicity, toxicity, topology, and immunogenicity using multiple bioinformatics methods and identified 4 CTL, 4 HTL, and 2 B-cell epitopes. The vaccine design was created by integrating an adjuvant and a PADRE sequence to enhance immunogenicity, along with linkers (AAY, GPGPG, KK) to facilitate appropriate structural assembly, which was then analyzed for optimal complete profiles. Molecular docking with the Bos taurus (cattle) TLR9 receptor demonstrated a robust binding affinity, scoring - 1183.4, while molecular dynamics (MD) simulations over 50 ns validated persistent interactions between the vaccine and immune receptors. Moreover, immunological models forecasted a robust adaptive immune response, marked by an increase in the production of cytokines and the establishment of memory T-lymphocytes. Ultimately, codon optimization and in silico cloning validated the capacity for effective expression in E. coli. The results demonstrate that the developed vaccine has considerable immunogenic potential against NC. Nonetheless, more in vitro and in vivo studies are necessary to confirm its efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.